Drug Type Small molecule drug |
Synonyms (2S)-2-Aminopentanedioic acid, (S)-2-Aminopentanedioic acid, (S)-Glutamic acid + [12] |
Target |
Mechanism GRIA2 agonists(glutamate ionotropic receptor AMPA type subunit 2 agonists), Amino acid replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization- |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date- |
Regulation- |
Molecular FormulaC5H9NO4 |
InChIKeyWHUUTDBJXJRKMK-VKHMYHEASA-N |
CAS Registry56-86-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00007 | Glutamic Acid |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hepatic Encephalopathy | CN | - | - |
Phase 3 | 250 | (Arm I Glutamic Acid) | amnetxykrv(ohmswkotha) = slupehmqra vzzaphisfj (prklseszfs, otidhfjbhr - nwrrxedguk) View more | - | 14 Mar 2014 | ||
placebo (Arm II Placebo) | amnetxykrv(ohmswkotha) = ekdymghuoh vzzaphisfj (prklseszfs, qpkybdvkwc - laeffzixqm) View more | ||||||
Not Applicable | - | - | L-glutamate 0.008-2.3 M/200 nl | yiqivsskwa(nnfvrehfrb) = vlouqbhzpw hkzjrxmwsq (lkalnjoonj, 1.3) | - | 14 Nov 2001 | |
L-glutamate 0.1 M | djosebmkav(ciypmodoey) = yhrdynjbau ybvfutswnn (qpqfvasswx ) View more |